FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management
Dockets Entered On March 27, 2006
Table of Contents
Docket # Title
1976N-0052N OTC Nasal Decongestants
1981N-0022 OTC Weight Control Drug Products for Human Use
1998P-0151 Introduction Of Downed Cattle Into The Food Supply
1998P-0724 Prohibition of Cochineal Extract and Carmine Color Additives
1999P-1340 Declared Eternity eau de Parfum Misbranded
2002D-0325 Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
2002P-0317 Recall Aspartame as a Neurotoxic Drug
2003N-0076 Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
2004H-0322 Civil Money Penalty Re: Ecumed Health Group, Inc.
2004P-0457 Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
2005D-0286 Draft Guidance for Industry on INDs Approaches to Complying with CGMP During Phase 1; Availability
2005H-0271 Civil Money Penalty: TMJ Implants, Inc.
2005M-0399 P020016 - Total Temporomandibular Joint Replacement System, Approved 9/21/05
2005M-0435 P960040/S028 - VENTAK PRIZM AVT AICD System, Approved 3/27/03
2005M-0454 P980022/S011 - Guardian RT
2005M-0473 P040003 - ExAblate 2000 System, Approved 10/22/04
2005M-0474 P040013 - GEM 21S (Growth-factor Enhanced Matrix), Approved 11/18/05
2005M-0475 P020045 - 7F Freezor Cardiac CryoAblation Catheter and CCT.2 CryoConsole System, Approved 4/17/03
2005M-0476 P040042 - Therapy Dual 8 Cardiac Ablation System, Approved 11/18/05
2005M-0477 P040047 -Coaptite, Approved 11/10/05
2005M-0478 P030056 - ADVIA Centaur HCV ReadyPack Reagents and ADVIA Centaur HCV Quality Control Materials, Approved December 22, 2004
2005M-0492 P030054/S010 - Epic and Atlas + HF CRT-D Systems
2005M-0504 P040045 - VISTAKON (senofilcon A) Contact Lens, Clear and Visibility Tinted with UV Blocker, Approved 12/20/05
2005N-0279 Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
2005N-0285 Current Good Manufacturing Practice Regulation and Investigational New Drugs
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
2006P-0129 to reclassify phenylpropanolamine(PPA) wieght control drug product from category I to category II
2006P-0131 Make a determination that Epirubicin Hydrochloride Injection, 2mg/ miin vialsizes of 10 mg/ 5 mi, 20 mg/ 10 mi and 200 mg/ 100 mi are suitable for submission in an ANDA.
2006P-0135 Issue Guidance to Industry outlining procedures and standards for initiating an "expanded access program" for unapproved drugs
2006V-0134 Laser Light Show
1976N-0052N OTC Nasal Decongestants
ACK 9 Wyeth Vol #: 1
C 245 Block Drug Company (Block) Vol #: 77
C 246 GlaxoSmithKline Consumer Healthcare, LP (GSK) Vol #: 77
C 247 Wyeth Consumer Healthcare Vol #: 77
CP 19 Wyeth Vol #: 86
1981N-0022 OTC Weight Control Drug Products for Human Use
CP 20 Wyeth Vol #: 98
1998P-0151 Introduction Of Downed Cattle Into The Food Supply
EMC 4390 R. Artley Vol #: 319
EMC 4391 C. Patterson Vol #: 319
EMC 4392 Rossi Family Vol #: 319
EMC 4393 M. Hermann Vol #: 319
EMC 4394 H. Hembrey Vol #: 319
1998P-0724 Prohibition of Cochineal Extract and Carmine Color Additives
EMC 20 D. Plumb Vol #: 3
1999P-1340 Declared Eternity eau de Parfum Misbranded
EMC 635 R. Goodrich Vol #: 24
2002D-0325 Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
EMC 242 K. Starling Vol #: 4
2002P-0317 Recall Aspartame as a Neurotoxic Drug
EMC 617 Mission Possible International Vol #: 9
EMC 618 Mission Possible International Vol #: 9
EMC 619 Mission Possible International Vol #: 9
2003N-0076 Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
EMC 1254 K. Kimball Vol #: 12
EMC 1255 No signature Vol #: 12
2004H-0322 Civil Money Penalty Re: Ecumed Health Group, Inc.
CS 22 HFA-305 Vol #: 10
OR 19 HF-3 to Ecumed Health Group, Amador Reyes, Juan Carrai, Richard W. Stone, & Erlinda E. Enrique Vol #: 10
2004P-0457 Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
ACK 2 HFA-305 to Endotec, Inc. Vol #: 5
CCP 2 Endotec, Inc. Vol #: 5
2005D-0286 Draft Guidance for Industry on INDs Approaches to Complying with CGMP During Phase 1; Availability
EMC 2 Japan Society of Pharmaceutical Machinery and Engineering (JSPME) Vol #: 1
2005H-0271 Civil Money Penalty: TMJ Implants, Inc.
CS 7 HFA-305 Vol #: 3
OR 7 HF-3 TO TMJ Implants, Inc. and Robert W. Christensen and Maureen K Mooney Vol #: 3
2005M-0399 P020016 - Total Temporomandibular Joint Replacement System, Approved 9/21/05
NAL 1 FDA Vol #: 1
2005M-0435 P960040/S028 - VENTAK PRIZM AVT AICD System, Approved 3/27/03
NAL 1 FDA Vol #: 1
2005M-0454 P980022/S011 - Guardian RT
NAL 1 FDA Vol #: 1
2005M-0473 P040003 - ExAblate 2000 System, Approved 10/22/04
NAL 1 FDA Vol #: 1
2005M-0474 P040013 - GEM 21S (Growth-factor Enhanced Matrix), Approved 11/18/05
NAL 1 FDA Vol #: 1
2005M-0475 P020045 - 7F Freezor Cardiac CryoAblation Catheter and CCT.2 CryoConsole System, Approved 4/17/03
NAL 1 FDA Vol #: 1
2005M-0476 P040042 - Therapy Dual 8 Cardiac Ablation System, Approved 11/18/05
NAL 1 FDA Vol #: 1
2005M-0477 P040047 -Coaptite, Approved 11/10/05
NAL 1 FDA Vol #: 1
2005M-0478 P030056 - ADVIA Centaur HCV ReadyPack Reagents and ADVIA Centaur HCV Quality Control Materials, Approved December 22, 2004
NAL 1 FDA Vol #: 1
2005M-0492 P030054/S010 - Epic and Atlas + HF CRT-D Systems
NAL 1 FDA Vol #: 1
2005M-0504 P040045 - VISTAKON (senofilcon A) Contact Lens, Clear and Visibility Tinted with UV Blocker, Approved 12/20/05
NAL 1 FDA Vol #: 1
2005N-0279 Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
EMC 300 F. Thacker Vol #: 23
EMC 301 Gluten Free Oats, LLC (GFO) Vol #: 23
2005N-0285 Current Good Manufacturing Practice Regulation and Investigational New Drugs
EMC 4 Plasma Protein Therapeutics Association (PPTA) Vol #: 1
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
C 4110 L. Mayton Vol #: 68
C 4111 B. Phillips, MD Vol #: 68
C 4112 S. Benson Vol #: 68
C 4113 C. Wimberg Vol #: 68
C 4114 S. Pennington Vol #: 68
C 4115 J. Robertson Vol #: 68
C 4116 F. Turley Vol #: 68
C 4117 M. Thomas Vol #: 68
C 4118 J. Werbinski, MD Vol #: 68
C 4119 C. Kurtz, MD Vol #: 68
C 4120 J. Werbinski, MD Vol #: 68
C 4121 J. Mullins Vol #: 68
C 4122 O. Whiddon Vol #: 68
C 4123 C. Barlow, MD Vol #: 68
C 4124 R. Erickson, MD, FAAFP Vol #: 68
C 4125 S. Fahrbach Vol #: 68
C 4126 J. Thomspon Vol #: 68
C 4127 C. Carlson Vol #: 68
C 4128 L. Wehr Vol #: 68
C 4129 K. Way Vol #: 68
C 4130 K. Stilwell Vol #: 68
C 4131 P. Hindeiberger, MD, PhD Vol #: 68
C 4132 Dr. D. Jacoby Vol #: 68
C 4133 J. Newfeld Vol #: 68
C 4134 M. Toth Vol #: 68
C 4135 L. Kenieczko Vol #: 68
C 4136 Dr. E. Simhbee Vol #: 68
C 4137 E. Miller Vol #: 68
C 4138 J. Sievers Vol #: 68
C 4139 J. Schultz Vol #: 68
C 4140 M. Rodriguez Vol #: 68
C 4141 S. Sass Vol #: 68
C 4142 J. Tester Vol #: 68
C 4143 C. Condit Vol #: 68
C 4144 M. Galvin Vol #: 68
C 4145 D. Stefko Vol #: 68
C 4146 F. Peterson Vol #: 68
C 4147 J. Jaime Vol #: 68
C 4148 C. Nichols Vol #: 68
C 4149 S. Monaghan Vol #: 68
C 4150 K. Treiber Vol #: 68
C 4151 S. LaRosa Vol #: 68
C 4152 R. Ferrara Vol #: 68
C 4153 G. Fatum Vol #: 68
C 4154 D. Chateauvert Vol #: 68
C 4155 D. McIver Vol #: 68
C 4156 K. Barton Vol #: 68
C 4157 E. Bauer Vol #: 68
C 4158 M. Reule Vol #: 68
C 4159 S. Ware Vol #: 68
C 4160 S. Rozier Vol #: 68
C 4161 C. Curtis Vol #: 68
C 4162 E. Skarbrevik Vol #: 68
C 4163 L. LaCava Vol #: 68
C 4164 J. Elliott Vol #: 68
C 4165 M. Anderson Vol #: 68
C 4166 F. Bacchelte Vol #: 68
C 4167 S. Ruth Vol #: 68
C 4168 L. Rechter Vol #: 68
C 4169 J. Feddern Vol #: 68
C 4170 B. Jackson-Davis Vol #: 68
C 4171 D. Dorste Vol #: 68
C 4172 M. Zepp Vol #: 68
C 4173 M. Bacon Vol #: 68
C 4174 B. Bieder Vol #: 68
C 4175 M. Posner Vol #: 68
C 4176 Y. Chapa Vol #: 68
C 4177 N. Koehler Vol #: 68
C 4178 S. Cook Vol #: 68
C 4179 P. Marble Vol #: 68
C 4180 K. Suomi Vol #: 68
C 4181 R. Miller Vol #: 68
C 4182 R. Stinson Vol #: 68
C 4183 S. Delaney Vol #: 68
C 4184 D. Alber Vol #: 68
C 4185 J. Kepka Vol #: 68
C 4186 S. Kelso Vol #: 68
C 4187 L. King Vol #: 68
C 4188 D. Gillespie Vol #: 68
C 4189 M. Troup Vol #: 68
C 4190 B. Sparre Vol #: 68
C 4191 F. Bianchi Vol #: 68
C 4192 S. Frederick Vol #: 68
C 4193 S. Wolford Vol #: 68
C 4194 K. Hoggatt Vol #: 68
C 4195 P. Taylor Vol #: 68
C 4196 D. Lookman Vol #: 68
C 4197 J. Klema, Jr. Vol #: 68
C 4198 M. Demarco Vol #: 68
C 4199 D. Hussey Vol #: 68
C 4200 M. Farley Vol #: 68
C 4201 M. Bell Vol #: 68
C 4202 A. Shiveley Vol #: 68
C 4203 Eligible Vol #: 68
C 4204 S. Cooter Vol #: 68
C 4205 R. Shore Vol #: 68
C 4206 B. Teel Vol #: 68
C 4207 C. Frazier Vol #: 68
C 4208 S. Collins Vol #: 68
C 4209 L. Breyer Vol #: 68
C 4210 P. Bergstrand Vol #: 68
C 4211 D. Strong Vol #: 68
C 4212 N. Karstedt Vol #: 68
C 4213 J. Russell Vol #: 68
C 4214 I. Weiner Vol #: 68
C 4215 V. Runyan Vol #: 68
C 4216 C. Wayne Vol #: 68
C 4217 J. Mullen Vol #: 68
C 4218 O. Morris, FNP Vol #: 68
C 4219 F. Garner Vol #: 68
C 4220 B. Thomson Vol #: 68
C 4221 R. Burhenn Vol #: 68
C 4222 K. Patla Vol #: 68
C 4223 R. HArt Vol #: 68
C 4224 P. Montero Vol #: 68
C 4225 S. Hoover Vol #: 68
C 4226 Y. Downs Vol #: 69
C 4227 C. Sckenrode Vol #: 69
C 4228 J. McKenzie Vol #: 69
C 4229 S. Schultz Vol #: 69
C 4230 S. Schultz Vol #: 69
C 4231 S. Hardy Vol #: 69
C 4232 V. Butters Vol #: 69
C 4233 J. Alk Vol #: 69
C 4234 C. Jones Vol #: 69
C 4235 D. Altman Vol #: 69
C 4236 D. Flack Vol #: 69
C 4237 E. McIntosh Vol #: 69
C 4238 B. Adams Vol #: 69
C 4239 J. Elder Vol #: 69
C 4240 C. Hughes Vol #: 69
C 4241 A. Light Vol #: 69
C 4242 E. Ham Vol #: 69
C 4243 E. Ham Vol #: 69
C 4244 L. BAker Vol #: 69
C 4245 Eligible Vol #: 69
C 4246 R. Bishop Vol #: 69
C 4247 P. Roberts Vol #: 69
C 4248 Eligible Vol #: 69
C 4249 M. Wall Vol #: 69
C 4250 E. Ledbetter Vol #: 69
C 4251 C. Phillips Vol #: 69
C 4252 S. Finney Vol #: 69
C 4253 G. Bailey Vol #: 69
C 4254 J. Walker Vol #: 69
C 4255 Eligible Vol #: 69
C 4256 S. Brierley Vol #: 69
C 4257 B. Garcia Vol #: 69
C 4258 N. Meyer Vol #: 69
C 4259 D. Treger Vol #: 69
C 4260 C. Rubis Vol #: 69
C 4261 L. Yucca Vol #: 69
C 4262 J. Gondreaou Vol #: 69
EMC 397 H. Spencer Vol #: 39
EMC 398 S. Singer Vol #: 39
EMC 399 M. Helin Vol #: 39
EMC 400 D. Abercrombie Vol #: 39
EMC 401 R. Shuman Vol #: 39
EMC 402 L. Jones Vol #: 39
EMC 403 M. McDonald Vol #: 39
EMC 404 G. Wilson Vol #: 39
EMC 405 D. Cross Vol #: 39
EMC 406 L. Baker Vol #: 39
EMC 407 M. Scharlack Vol #: 39
EMC 408 R. Fairchild Vol #: 39
EMC 409 M. Gross Vol #: 39
EMC 410 K. Schock Vol #: 39
EMC 411 K. Stratvert Vol #: 39
EMC 412 C. Weber Vol #: 39
EMC 413 D. Doheny Vol #: 39
EMC 414 M. West Vol #: 39
EMC 415 S. Minoli Vol #: 39
EMC 416 M. Swenson Vol #: 39
EMC 417 R. Walton Vol #: 39
EMC 418 S. MacQuarrie Vol #: 39
EMC 419 C. Besso Vol #: 39
EMC 420 O. Berntsen Jr. Vol #: 39
EMC 421 K. Lankford Vol #: 39
EMC 422 A. Castellano Vol #: 39
EMC 423 S. McKee Vol #: 39
EMC 424 M. Jordan Vol #: 39
EMC 425 D. Ritter Vol #: 39
EMC 426 E. McCool Vol #: 39
EMC 427 T. Carpenter Vol #: 39
EMC 428 J. Beutel Vol #: 39
EMC 429 K. Switzer Vol #: 39
EMC 430 V. Lawrence Vol #: 39
EMC 431 R. Rufe Vol #: 39
EMC 432 J. BenAmoz, R.Ph Vol #: 39
EMC 433 L. Becker Vol #: 39
EMC 434 D. Chamberlin Vol #: 39
EMC 435 E. Finders Vol #: 39
EMC 436 R. Twait Vol #: 39
EMC 437 R. Robertson Vol #: 39
EMC 438 J. Hutson Vol #: 39
EMC 439 J. Hutson Vol #: 39
EMC 440 K. Ivey Vol #: 39
EMC 441 V. Barre Vol #: 39
EMC 442 L. Benson Vol #: 39
EMC 443 D. Chen Vol #: 39
EMC 444 J. Black Vol #: 39
EMC 445 M. Townsend Vol #: 39
EMC 446 H. Simon Vol #: 39
EMC 447 K. Clark Vol #: 39
EMC 448 J. Helder Vol #: 39
EMC 449 F. Holzbach Vol #: 39
EMC 450 A. Pulley Vol #: 39
EMC 451 J. Slatton Vol #: 76
EMC 452 K. Boozan Vol #: 76
EMC 453 A. Rosenberg Vol #: 76
EMC 454 B. Nasser Vol #: 76
EMC 455 B. Nadelman Vol #: 76
EMC 456 M. Deane Vol #: 76
EMC 457 R. Weir Vol #: 76
EMC 458 L. Tuttle Vol #: 76
EMC 459 K. Wolfe Vol #: 76
EMC 460 I. Papagno Vol #: 76
EMC 461 H. Mueller Vol #: 76
EMC 462 M. Edmondson Vol #: 76
EMC 463 P. Becker Vol #: 76
EMC 464 S. Reynolds Vol #: 76
EMC 465 M. Baker Vol #: 76
EMC 466 H. Tilgner Vol #: 76
EMC 467 E. MacInnis Vol #: 76
EMC 468 C. Oakleaf Vol #: 76
EMC 469 E. Page Vol #: 76
EMC 470 Y. Glendennin Vol #: 76
EMC 471 D. Saner Vol #: 76
EMC 472 S. Babiar Vol #: 76
EMC 473 J. Kenessey Vol #: 76
EMC 474 T. Hawkins Vol #: 76
EMC 475 J. Buckner Vol #: 76
EMC 476 J. Kenessey Vol #: 76
EMC 477 M. Giguere Vol #: 76
EMC 478 C. Bailey Vol #: 76
EMC 479 P. McPeak Vol #: 76
EMC 480 J. Stoner Vol #: 76
EMC 481 R. Sica, MD Vol #: 76
EMC 482 D. Stoner Vol #: 76
EMC 483 R. Dargan Vol #: 76
EMC 484 M. Bosna Vol #: 76
EMC 485 P. Battersby Vol #: 76
EMC 486 R. Conrad Vol #: 76
EMC 487 V. Master Vol #: 76
EMC 488 M. Frendel Vol #: 76
EMC 489 B. Minces Vol #: 76
EMC 490 C. Cassidy Vol #: 76
EMC 491 J. Hoagland Vol #: 76
EMC 492 D. Henry Vol #: 76
EMC 493 J. Bodfield Vol #: 76
EMC 494 M. Hatfield Vol #: 76
EMC 495 J. Sherwood Vol #: 76
EMC 496 D. Camilli Vol #: 76
EMC 497 C. Mills Vol #: 76
EMC 498 E. Karickhoff Vol #: 76
EMC 499 R. Sheperd Vol #: 76
EMC 500 K. Willis Vol #: 76
EMC 501 G. Glass Vol #: 76
EMC 502 A. Gardner Vol #: 76
EMC 503 J. Kelly Vol #: 76
EMC 504 S. Miller Vol #: 76
EMC 505 R. Walstra Vol #: 76
EMC 506 A. Wood Vol #: 76
EMC 507 S. Miller Vol #: 76
EMC 508 K. Stout Vol #: 76
EMC 509 G. Tilley Vol #: 76
EMC 510 S. Gates Vol #: 76
EMC 511 K. Hays Vol #: 76
EMC 512 C. Morris Vol #: 76
EMC 513 E. Skeen Vol #: 76
EMC 514 D. Fraley Vol #: 76
EMC 515 L. Jackson Vol #: 76
EMC 516 R. Malone Vol #: 76
EMC 517 L. Pines Vol #: 76
EMC 518 M. Hamilton Vol #: 76
EMC 519 M. Dib Vol #: 76
EMC 520 S. Rehorn Vol #: 76
EMC 521 B. Williamson Vol #: 76
EMC 522 R. Bush Vol #: 76
EMC 523 M. Cox Vol #: 76
EMC 524 J. Kolber Vol #: 76
EMC 525 E. Peterson Vol #: 76
2006P-0129 to reclassify phenylpropanolamine(PPA) wieght control drug product from category I to category II
ACK 1 number not used Vol #: 1
2006P-0131 Make a determination that Epirubicin Hydrochloride Injection, 2mg/ miin vialsizes of 10 mg/ 5 mi, 20 mg/ 10 mi and 200 mg/ 100 mi are suitable for submission in an ANDA.
ACK 1 HFA-305 to AAC Consulting Group Vol #: 1
CP 1 AAC Consulting Group Vol #: 1
  2006P-0135 Issue Guidance to Industry outlining procedures and standards for initiating an "expanded access program" for unapproved drugs
ACK 1 HFA-305 to National Coalition for Cancer Survivorship and American Society of Clinical Oncology Vol #: 1
CP 1 National Coalition for Cancer Survivorship and American Society of Clinical Oncology Vol #: 1
2006V-0134   Laser Light Show            
ACK 1 HFA-305 to Fun City LLC Vol #: 1
VAR 1 Fun City LLC Vol #: 1

Page created on May 24, 2006 kk

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management